NEW YORK, Oct. 24 - Abbott Laboratories has agreed to acquire Vysis in a stock deal worth about $355 million in an attempt to buttress its position in the DNA-based diagnostic market, the drug giant announced on Wednesday.

Abbott will pay $30.50 per share for Vysis, which is a 33 percent premium on Vysis shares, the company said. Shares in the Downers Grove, Illinois-based company closed at $23 on the Nasdaq on Tuesday.

Vysis manufactures and markets two tests that detect certain genetic markers for breast and bladder cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.